In heart failure, all beta-blockers are not necessarily equal

Cleveland Clinic Journal of Medicine

Volumn 70, Issue 12, 2003, Pages 1081-1087

  Tang, W H Wilson ^a   Militello, Michael ^a   Francis, Gary S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BISOPROLOL FUMARATE; BISOPROLOL FUMARATE PLUS HYDROCHLOROTHIAZIDE; BUCINDOLOL; CARVEDILOL; METOPROLOL; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; PLACEBO;

ARTICLE; BRADYCARDIA; CLINICAL STUDY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG USE; EVIDENCE BASED MEDICINE; HEART FAILURE; HUMAN; HYPOTENSION; SURVIVAL; SUSTAINED RELEASE FORMULATION;

EID: 0346102796     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.70.12.1081     Document Type: Article

References (29)

1. Poole-Wilson PA, Swedberg K, Cleland JGF, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003; 362:7-13.
2. MERIT-HF Investigators. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353:2001-2007.
3. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353:9-13.
4. Packer M, Bristow M, Cohn J, et al. The effect of carvedilol on mortality and morbidity in patients with chronic heart failure. N Engl J Med 1996; 334:1349-1355.
5. Packer M, Coats AJ, Fowler M, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344:1659-1667.
6. The CAPRICORN investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001; 357:1385-1390.
7. Kukin ML. Beta-blockers in chronic heart failure: considerations for selecting an agent. Mayo Clin Proc 2002; 77:1199-1206.
8. Frishman WH. Carvedilol. N Engl J Med 1998; 339:1759-1765.
9. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001; 344:1659-1667.
10. Kukin ML, Kalman J, Charney RH, et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 1999; 99:2645-2651.
11. Metra M, Giubbini R, Nodari S, et al. Differential effects of beta-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 2000; 102:546-551.
12. Sanderson JE, Chan SJ, Yip G, et al. Beta-blockade in heart failure: a comparison of carvedilol with metoprolol. J Am Coll Cardiol 1999; 34:1522-1528.
13. Gilbert EM, Abraham WT, Olsen S, et al. Comaprative hemodynamic, left ventricular functional, and antiadrenergic effects of long-term treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996; 94:2817-2825.
14. Di Lenarda A, Sabbadini G, Salvatore L, et al. Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. J Am Coll Cardiol 1999; 33:1926-1934.
15. Maack C, Elter T, Nickenig G, et al. Prospective crossover comparison of carvedilol and metoprolol in patients with chronic heart failure. J Am Coll Cardiol 2001; 38:939-946.
16. Rajput FS, Gnanasekeram H, Satwani S, et al. Choosing metoprolol or carvedilol in heart failure (a pre-COMET commentary). Am J Cardiol 2003; 92:218-221.
17. Poole-Wilson PA. Clinical Trials Update II (Heart Failure) - The Carvedilol Or Metoprolol European Trial (COMET). Presented at the European Society of Cardiology Congress 2003. Vienna, Austria; 2003.
18. Mehra MR, Uber PA, Francis GS. Heart failure therapy at a crossroad: are there limits to the neurohormonal model? J Am Coll Cardiol 2003; 41:1606-1610.
19. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999; 100:2312-2318.
20. Butler J, Khadim G, Belue R, et al. Tolerability to beta-blocker therapy among heart failure patients in clinical practice. J Card Fail 2003; 9:203-209.
21. Prakash A, Markham A. Metoprolol: a review of its use in chronic heart failure. Drugs 2000; 60:647-678.
22. Sandberg A, Blomqvist I, Jonsson UE, et al. Pharmacokinetic and pharmacodynamic properties of a new controlled-release formulation of metoprolol: a comparison with conventional tablets. Eur J Clin Pharmacol 1988; 33:S9-S14.
23. Darmansjah I, Wong E, Setiawati A, et al. Pharmacokinetic and pharmacodynamic properties of controlled release (CR/ZOK) metoprolol in healthy Oriental subjects: a comparison with conventional formulations of metoprolol and atenolol. J Clin Pharmacol 1990; 30:S39-S45.
24. Andersson B, Aberg J, Lindelow B, et al. Dose-related effects of metoprolol on heart rate and pharmacokinetics in heart failure. J Card Fail 2001; 7:311-317.
25. Hjalmarson A, Waagstein F. Response to COMET from MERIT-HF Investigators. In: Forum (theheart.org); 2003.
26. Kukin ML, Mannino MM, Freudenberger RS, et al. Hemodynamic comparison of twice daily metoprolol tartrate with once daily metoprolol succinate in congestive heart failure. J Am Coll Cardiol 2000; 35:45-50.
27. Kukin ML, Kalman J, Mannino MM, et al. Beta blockade in congestive heart failure: persistent adverse haemodynamic effects during chronic treatment with subsequent doses. Heart 1997; 78:444-449.
28. Sandberg A, Abrahamsson B, Regardh CG, et al. Pharmacokinetic and biopharmaceutic aspects of once daily treatment with metoprolol CR/ZOK: a review article. J Clin Pharmacol 1990; 30:S2-S16.
29. Dargie HJ. Beta blockers in heart failure. Lancet 2003; 362:2-3.